Clinical trial
A Correlative Study for Predicting Response and Toxicity in Patients Receiving…
NCT00235235 · Hoosier Cancer Research Network, Other · Terminated
Key facts
| NCT number | NCT00235235 |
|---|---|
| Title | A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer |
| Official title | Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01 |
| Lead sponsor | Hoosier Cancer Research Network, Other |
| Collaborators | United States Department of Defense U.S. Fed Indiana University School of Medicine Walther Cancer Institute |
| Status | Terminated |
| Study type | Observational |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Biopsy, Serum Collection, Urine Collection, Doxorubicin, Cyclophosphamide, Capecitabine, Vinorelbine, Gemcitabine |
| Enrollment | 80 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Oct 10, 2005 |
| Last update posted | Dec 9, 2015 |
| Countries | Peru, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: